AHFS Class:

10:00 Antineoplastic Agents

Mosunetuzumab-axgb is available as a 1-mg/mL concentrate for injection in 1- and 30-mL preservative-free single-dose vials.³⁹⁷⁵ Each 1-mL vial contains mosunetuzumab-axgb 1 mg, acetic acid 0.4 mg, histidine 1.6 mg, methionine 1.5 mg, polysorbate 20 0.6 mg, and sucrose 82.1 mg in water for injection.³⁹⁷⁵ Each 30-mL vial contains mosunetuzumab-axgb 30 mg, acetic acid 12.8 mg, histidine 46.6 mg, methionine 44.8 mg, polysorbate 20 18 mg, and sucrose 2462.4 mg in water for injection.³⁹⁷⁵ The concentrate for injection must be diluted in sodium chloride 0.9 or 0.45% prior to administration.³⁹⁷⁵ To prepare a diluted solution for administration, a volume of infusion solution equivalent to the volume of the concentrate for injection to be added should be removed from an infusion bag containing sodium chloride 0.9 or 0.45% before transferring the appropriate volume of mosunetuzumab-axgb concentrate for injection to the infusion bag.³⁹⁷⁵ The size of the infusion bag depends on the dose of mosunetuzumab-axgb; doses of 1 or 2 mg may be diluted in a 50- or 100-mL infusion bag, doses of 30 mg may be diluted in a 50-, 100-, or 250-mL infusion bag, and doses of 60 mg should be diluted in a 100- or 250-mL infusion bag.³⁹⁷⁵ The diluted solution should be mixed gently by inversion; do not shake.³⁹⁷⁵

pH

The concentrate for injection has a pH of 5.8.³⁹⁷⁵

Trade Name(s)

Lunsumio

Mosunetuzumab-axgb is administered by intravenous infusion over a minimum of 2 or 4 hours, depending on the treatment cycle.³⁹⁷⁵ Diluted solutions for infusion should be at room temperature at the time of infusion.³⁹⁷⁵

Intact vials should be stored at 2 to 8°C in the original carton to protect from light.³⁹⁷⁵ Do not freeze or shake.³⁹⁷⁵

Mosunetuzumab-axgb concentrate for injection is a colorless solution; do not use if the solution is discolored, cloudy, or contains particulate matter.³⁹⁷⁵

Diluted solutions may be stored for up to 24 hours at 2 to 8°C, or up to 16 hours at ambient room temperature (9 to 30°C).³⁹⁷⁵ If refrigerated, diluted solutions should be allowed to come to room temperature prior to administration.³⁹⁷⁵

Sorption

Manufacturer states the final diluted solution for infusion should be prepared only in infusion bags composed of polyvinyl chloride (PVC) or polyolefins such as polyethylene and polypropylene.³⁹⁷⁵

In addition, no incompatibilities have been observed between mosunetuzumab-axgb and infusion sets or products containing PVC, polyethylene, polyurethane, polybutadiene, silicone, acrylonitrile butadiene styrene, polycarbonate, polyetherurethane, fluorinated ethylene propylene, or polytetrafluorethylene, or with drip chamber filter membranes composed of polyamide.³⁹⁷⁵

Filtration

Manufacturer states that an inline filter should not be used for administration.³⁹⁷⁵

Solution Compatibility

For a list of references cited in the text of this monograph, search the monograph titled References.

ASHP^® Injectable Drug Information^TM. Selected Revisions December 5, 2024. © Copyright, 2025. American Society of Health-System Pharmacists^®, 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.